GSK receives FDA approval for Lamictal XR

RESEARCH TRIANGLE PARK, N.C. The Food and Drug Administration has approved a long-acting formulation of an epilepsy drug.

British drug maker GlaxoSmithKline announced Monday the approval of Lamictal XR (lamotrigine) as a once-daily add-on therapy for epilepsy patients aged 13 and older with partial-onset seizures.

“Many patients require multiple doses of one or more medications to control their epilepsy, which makes taking their medicines even more challenging,” University of South Alabama professor and chairman of neurology Dean Naritoku said. “Lamictal XR is an important once-daily advance for patients with epilepsy who still experience seizures while taking their current therapy.”